Ipragliflozin API is a pharmaceutical-grade Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor indicated for the treatment of Type 2 Diabetes Mellitus. It lowers blood glucose by selectively inhibiting SGLT2 in the kidneys, reducing glucose reabsorption and promoting urinary glucose excretion.
In addition to glycemic control, Ipragliflozin may contribute to weight reduction, blood pressure improvement, and overall metabolic management. It is commonly formulated into oral tablet formulations and may be used as monotherapy or in combination with other antidiabetic agents.
Manufactured under WHO-GMP-certified facilities, our Ipragliflozin API is produced using advanced pharmaceutical manufacturing processes to ensure exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes stringent quality testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Ipragliflozin API is used in oral pharmaceutical formulations for the treatment of Type 2 Diabetes Mellitus to improve glycemic control.
Ipragliflozin selectively inhibits SGLT2 in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Ipragliflozin API in commercial quantities with worldwide export support and customized packaging.
Get Bulk Quote via WhatsApp